ArticleAnnals of surgical oncology2026
Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab.
Junichi Shindoh et al.PubMed ↗Publisher ↗
No numbers read from the abstract.